With ongoing clinical studies on IDH1/2 inhibition combined with high-intensity induction regimen for newly diagnosed AML23–25, our data suggest that cladribine might be a potent combination partner for multi-agent therapy of IDH2+ AML patients. The gene discussed is IDH1; the disease is acute myeloid leukemia.